

Confirmed Speakers

Plenary Speakers

Towards an Understanding of Cellular Drug Efficiency as a Way to Control Molecular Obesity (PL20)

Paul Ehrlich Prize Lecture Trip in Drug Discovery (PL01)



Prof. Jean-Daniel BRION
(UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France)

The Discovery and Optimization of Benzimidzoles as Selective NAV1.8 Blockers for the Treatment of Pain (PL06)



Dr Alan BROWN
(STRATIFIED MEDICAL, Deal, United Kingdom)

Conquering the p53-MDM2 Protein-Protein Interaction Target at Novartis (PL21)



Dr Pascal FURET
(NOVARTIS, Basel, Switzerland)

Advances in Structure Based Drug Discovery of Membrane Protein Targets (PL14)



Dr Michael HENNIG
(LEADXPPO, Villigen, Switzerland)

Discovery of the Type II Kinase Inhibitor LY3009120; a Pan-RAF Inhibitor Showing Minimal Paradoxical Activation and Anti-Cancer Activity Against BRAF or RAS Mutant Tumor Cells (PL22)



Dr James R. HENRY
(ELI LILLY & CO., Indianapolis, United States)

Nanocyclix: a Chemical Biology Approach for Next Generation Kinase Inhibitors (PL08)



Dr Jan HOFACK
(ONCODESIGN, Dijon, France)

Molecular Imaging Agents Based on Lanthanide Complexes (PL17)



Dr Eva JAKAB-TOTH
(CNRS, Orléans, France)

Optimization and Exploration of Bradykinin 1 Receptor Antagonists for Inflammation (PL07)



Dr Sven KÜHNERT
(GRUENENTHAL GMBH, Aachen, Germany)

Confirmed Speakers

Human Proteomes – from Basic Biology to Understanding Drug Action (PL02)



Prof. Bernhard KÜSTER
(TECHNICAL UNIVERSITY MUNICH, Munich, Germany)

Protein Total Synthesis and the Challenge of Understanding MET Tyrosine Kinase Receptor Activation (PL11)



Dr Oleg MELNYK
(CNRS / UNIVERSITY OF LILLE / PASTEUR INSTITUTE OF LILLE, Lille, France)

The Realisation of Activity-Directed Synthesis (PL19)



Prof. Adam NELSON
(UNIVERSITY OF LEEDS, Leeds, United Kingdom)

Discovery of Selective Dopaminergic D3 Receptor Antagonists with Potent 5HT6 Affinity (PL10)



Dr Jean-Claude ORTUNO
(INSTITUT DE RECHERCHES SERVIER, SURESNES, France)

Innovative Approaches to Control Metabotropic Glutamate Receptor Activity in the Brain (PL15)



Dr Jean-Philippe PIN
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)

MT5-MMP, a New Potential Therapeutic Target in Alzheimer's Disease (PL09)



Dr Santiago RIVERA
(CNRS / AIX-MARSEILLE UNIVERSITY, Marseille, France)

Development of Novel Antiangiogenic Agents for the Treatment of Retinal Neovascularization via Integration of Chemistry and Biology (PL12)



Prof. Young-Ger SUH
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South)

Protein Modification: from Chemical Biology to Drug Discovery (PL04)



Prof. Edward TATE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Novel Fluorogenic Probes for In Vivo Imaging of Tiny Tumors and Super-Resolution Imaging in Living Cells (PL18)

Confirmed Speakers



Prof. Yasuteru URANO
(THE UNIVERSITY OF TOKYO, Tokyo, Japan)

The Design of mGluR Modulators for CNS Disorders (PL16)



Dr Michiel VAN GOOL
(JANSSEN R&D, Toledo, Spain)

Design of Chemical Probes Acting on Emerging Targets Assisted by Online Computational Tools (PL13)



Dr Bruno VILLOUTREIX
(INSERM/UNIVERSITY PARIS DIDEROT, Paris, France)

Pierre Fabre Award for Therapeutic Innovation A Scien-trepreneur Journey From Digital to In-vivo Organic Chemistry (PL23)



Dr Alain WAGNER
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

A Role of SIRT2 in Cellular Response to Environmental Signals (PL05)



Dr Minoru YOSHIDA
(RIKEN ADVANCED SCIENCE INSTITUTE (ASI), Saitama, Japan)

Target Deconvolution Efforts Around Wnt Pathway Screen Reveal Parallel Mechanisms of Action for 1,2,3-Thiadiazole-5-Carboxamide Series (PL03)



Dr Andrew ZHANG
(ASTRAZENECA R&D, Waltham, United States)

Keynote Speakers

Development of Potent Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) (KL03)



Dr Céline CANO
(NEWCASTLE CANCER CENTRE, Newcastle upon Tyne, United Kingdom)

Original Serotonergic Multi-Target Directed Ligands against Alzheimer's Disease (KL02)



Dr Sylvie CLAEYSEN
(INSTITUT DE GÉNOMIQUE FONCTIONNELLE / CNRS / INSERM, Montpellier, France)

Discovery of GLPG1690: a First-in-Class Autotaxin Inhibitor in Clinical Development for the Treatment of Idiopathic Pulmonary Fibrosis (KL01)

Confirmed Speakers



Dr Nicolas DESROY
(GALAPAGOS, Romainville, France)

Fragment-Based Design of ITK Inhibitors (KL06)



Dr Steven DURRANT
(VERTEX PHARMACEUTICALS (EUROPE) LTD, Abingdon, United Kingdom)

E.coli Anti-Adhesives, Potential Therapeutics for Crohn's Disease? (KL08)



Dr Sébastien GOUIN
(UNIVERSITY OF NANTES, Nantes, France)

Structure Guided Drug Discovery: Merits and Pitfalls Through the Example of Two Kinase Projects (KL04)



Dr Andras KOTSCHY
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary)

NMR for Chemical Biology and Drug Discovery (KL05)



Dr Isabelle KRIMM
(CNRS / UNIVERSITY OF LYON 1, Villeurbanne, France)

Inhibiting Chromatin Assembly by Targeting Histone Chaperones (KL07)



Dr Françoise OCHSENBEIN
(CEA SACLAY, Gif-sur-Yvette, France)